Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin

Simple item page
dc.contributor.authorLamorde, Mohammed
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorOkaba-Kayom, Violet
dc.contributor.authorRyan, Mairin
dc.contributor.authorCoakley, Peter
dc.contributor.authorBoffito, Marta
dc.contributor.authorNamakula, Rhoda
dc.contributor.authorKalemeera, Francis
dc.contributor.authorColebunders, Robert
dc.contributor.authorBack, David
dc.contributor.authorKhoo, Saye
dc.contributor.authorMerry, Concepta
dc.date.accessioned2022-01-12T12:16:33Z
dc.date.available2022-01-12T12:16:33Z
dc.date.issued2011
dc.description.abstractIn resource-poor countries, HIV and tuberculosis (TB) co-infection results in significant morbidity and mortality. Co-treatment is recommended by the WHO;1 however, drug interactions are common between anti-TB regimens containing rifampicin and antiretroviral drugs. In these settings, rifampicin is a key drug for TB treatment because alternative rifamycins are more expensive and usually not available in public TB control programmes. Similarly, for HIV treatment, only a limited number of antiretroviral drugs are routinely used. The problems arising from limited drug options are compounded by the wide use of fixed-dose combination (FDC) formulations for both diseases. When these formulations are used, drug substitutions are not possible and dose adjustments are usually difficult.en_US
dc.identifier.citationLamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., ... & Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq411en_US
dc.identifier.other10.1093/jac/dkq411
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1227
dc.language.isoenen_US
dc.publisherJournal of Antimicrobial Chemotherapyen_US
dc.subjectPKen_US
dc.subjectAntimycobacterial agentsen_US
dc.subjectHIV antiviral pharmacologyen_US
dc.titleNevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicinen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.pdf
Size:
165.5 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences